- Home
- NGVC vs ABUS Comparison
NGVC vs ABUS Comparison
Compare NGVC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NGVC | ABUS |
|---|---|---|
| Founded | 1955 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.4M | 888.5M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | NGVC | ABUS |
|---|---|---|
| Price | $24.90 | $4.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 271.1K | ★ 1.4M |
| Earning Date | 02-05-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | ★ 36.05 | N/A |
| EPS | ★ 2.00 | N/A |
| Revenue | ★ $1,330,836,000.00 | $14,606,000.00 |
| Revenue This Year | $7.83 | $125.30 |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $12.67 | ★ N/A |
| Revenue Growth | 7.19 | ★ 116.64 |
| 52 Week Low | $23.47 | $2.71 |
| 52 Week High | $61.22 | $5.10 |
Technical Indicators
Market Signals| Indicator | NGVC | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 53.35 |
| Support Level | $23.47 | $4.39 |
| Resistance Level | $25.95 | $5.00 |
| Average True Range (ATR) | 0.89 | 0.23 |
| MACD | 0.25 | -0.02 |
| Stochastic Oscillator | 51.40 | 53.79 |
Price Performance
Historical ComparisonAbout NGVC Natural Grocers by Vitamin Cottage Inc.
Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories, natural and organic food, dietary supplements, natural body care, household, pet care products, books and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business are conducted. The company generates the majority of its revenue from grocery products and dietary supplements and rest from other products.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.